title: Does ruxolitinib prolong the survival of patients with myelofibrosis?
authors.affiliation: Hematology Department, Hospital Clínic, Institut d'Investigacions Biomèdiques August Pi i Sunyer, University of Barcelona, Barcelona, Spain; and.
authors.forename: Francisco
authors.initials: F
authors.lastname: Cervantes
authors.affiliation: Hemotherapy Department, Hospital Clínic, Barcelona, Spain.
authors.forename: Arturo
authors.initials: A
authors.lastname: Pereira
mesh_terms: D000368:Aged; D016022:Case-Control Studies; D017326:Clinical Trials, Phase III as Topic; D055317:Evidence-Based Practice; D006801:Humans; D000075242:Janus Kinase Inhibitors / Q000627:therapeutic use; D008297:Male; D009570:Nitriles; D055728:Primary Myelofibrosis / Q000188:drug therapy* / Q000401:mortality; D011720:Pyrazoles / Q000627:therapeutic use*; D011743:Pyrimidines; D016032:Randomized Controlled Trials as Topic; D013163:Splenomegaly / Q000188:drug therapy; D016019:Survival Analysis; D016896:Treatment Outcome
chemical_list: D000075242:Janus Kinase Inhibitors; D009570:Nitriles; D011720:Pyrazoles; D011743:Pyrimidines; C540383:ruxolitinib